Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ardizzoni

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Cancer Chemotherapy and Pharmacology|February 5, 2013
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancerG Bisagni, A Musolino, M Panebianco, et al.
British Journal of Cancer|September 25, 1999
Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancerA Ardizzoni, F Grossi, T Scolaro, et al.
The European Respiratory Journal|May 8, 1999
Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysisA M Orengo, L Spoletini, A Procopio, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancerM Venturini, L Del Mastro, F Testore, et al.
Cancer|December 18, 2001
Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinomaA Ardizzoni, M A Cafferata, M Paganuzzi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development GroupG Giaccone, E F Smit, M de Jonge, et al.
British Journal of Cancer|December 7, 2007
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activationS Cascinu, R Berardi, S Salvagni, et al.
British Journal of Cancer|December 19, 2007
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapyF V Negri, N Campanini, R Camisa, et al.
Cancer|August 16, 2001
Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)H S Parra, L Tixi, F Latteri, et al.
British Journal of Cancer|April 4, 2013
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatinM Tiseo, P Bordi, B Bortesi, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Cancer Chemotherapy and Pharmacology|February 5, 2013
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancerG Bisagni, A Musolino, M Panebianco, et al.
British Journal of Cancer|September 25, 1999
Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancerA Ardizzoni, F Grossi, T Scolaro, et al.
The European Respiratory Journal|May 8, 1999
Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysisA M Orengo, L Spoletini, A Procopio, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancerM Venturini, L Del Mastro, F Testore, et al.
Cancer|December 18, 2001
Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinomaA Ardizzoni, M A Cafferata, M Paganuzzi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development GroupG Giaccone, E F Smit, M de Jonge, et al.
British Journal of Cancer|December 7, 2007
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activationS Cascinu, R Berardi, S Salvagni, et al.
British Journal of Cancer|December 19, 2007
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapyF V Negri, N Campanini, R Camisa, et al.
Cancer|August 16, 2001
Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)H S Parra, L Tixi, F Latteri, et al.
British Journal of Cancer|April 4, 2013
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatinM Tiseo, P Bordi, B Bortesi, et al.
Pageof 16